Contents
Contents
Pharmacy PBM fraud questions turn on what the payer was told, what happened to the prescription and where the money went. A pharmacy can receive payment for medicine the patient never collects. A PBM can promise every rebate while its contract excludes whole categories of manufacturer payments. If you know the claim field, software setting or contract definition behind that difference, you may know the part of the transaction that makes a whistleblower case.
An integrated business can process the claim, dispense the medicine and receive manufacturer payments, with a different agreement and set of accounts for each. We follow the money across those roles.
That matters when an employee says the company kept the money. We need to know which company received it, what the payment bought and what another party was told about it. Pharmacy reimbursement, the sponsor’s charge and a manufacturer’s rebate belong to different parts of the same inquiry.
No. A paid claim shows a billing result. Pickup and delivery records show whether the patient received the medicine. Uncollected prescriptions require a comparison between the order, dispensing record, pickup or shipment, return to stock, claim reversal and money returned.
New York’s NYRx pharmacy policy expressly distinguishes claim submission from proof that the prescription was furnished. For Medicare Part D, the sponsor also submits Prescription Drug Event data to the Centers for Medicare & Medicaid Services. Those data are summary extracts, so we connect them back to the pharmacy transaction and any later correction.
Walgreens agreed to $31.5 million in new payments, in addition to prior refunds, under the settlement covering its central prescription queue. The government alleged that unsold or undeleted orders moved after 29 days into a central Unaccounted-For Status, outside local work queues, without a separate process to resolve them. The local queue could look clear while the claim remained unresolved.
We should expect more from a paid prescription than an empty work queue. The question is where the medicine went and whether the payer got its money back.
Minnesota’s Medical Assistance manual, revised August 3, 2026, requires an explicit request from the member or authorized caregiver for each refill, based on continued medical necessity, and disallows automatic refills. A request, a valid prescription and the amount of medicine still on hand answer different questions. In the CVS insulin case, the government alleged that software calculated refill dates from inaccurate days-of-supply entries and prompted patients to collect premature refills. The supply figure that sets the next refill date therefore belongs beside the quantity actually dispensed and the prescriber’s dosing instructions.
Some PBM rules allowed a capped supply value in the claim while requiring the pharmacy to calculate the next refill from the actual supply. We examine both values and the software’s use of them. A billing convention should not make the patient need insulin sooner.
A new prescription number cannot supply the prescriber’s missing authorization. In its complaint against Omnicare, the government alleged that the pharmacy continued dispensing after prescriptions expired or exhausted their authorized refills. The complaint quoted a compliance officer describing what the system allowed:
An issue that I am running into more and more in multiple states concerns the ability of our systems to allow prescriptions to continue to roll after a year to a new prescription number without any documentation or pharmacist intervention.
Compliance officer’s words quoted in the government’s complaint, United States ex rel. Bassan v. Omnicare, Inc., paragraph 11
The operational question in that email remains direct: what authorized the next prescription number? A pharmacist or systems employee may know whether the change came from a prescriber or from the software.
It covers the receipts the agreement defines as rebates. The definition determines which manufacturer payments and affiliate receipts reach the sponsor.
Minnesota’s Caremark agreement effective in 2021 includes specified formulary, market-share, price-protection, administrative and program payments. It excludes described mail-order and specialty purchasing discounts and specified specialty service revenues. Its full pass-through promise applies to that defined category, including covered receipts of the PBM or an affiliate.
The percentage gets the attention. The definition does the work.
For an insider handling manufacturer payments or contract reconciliation, the useful comparison joins the manufacturer’s agreement, the recipient, the payment classification, eligible claims and the final contract reconciliation. We want to know whether money that belonged inside the promised category was placed outside it, and who made that decision.
Spread pricing shows the difference between what the sponsor pays the PBM and what the PBM pays the pharmacy. We ask whether the plan paid more because the PBM misrepresented the pharmacy cost or withheld a promised credit.
The sponsor agreement sets one side of the transaction. The pharmacy network agreement sets the other. Later contract adjustments can change the final amounts. An affiliated pharmacy has its own dispensing revenue and costs, while manufacturer agreements can add rebate or service income.
We compare the sponsor invoice, pharmacy remittance and final reconciliation to see whether the payer received the promised price and credits. Patient cost sharing is another amount. Where coinsurance uses the price at the counter, a later manufacturer rebate can reduce the sponsor’s net cost while the patient’s share remains tied to that earlier price.
No. A clawback can recover money on a pharmacy claim. Direct and indirect remuneration, usually called DIR, is part of Medicare Part D’s accounting for concessions that reduce drug costs. A claim correction and an annual reconciliation can concern the same prescription while doing different work.
The Centers for Medicare & Medicaid Services’ post-point-of-sale guidance separates those events. When the drug was not dispensed, or the claim was duplicated, the guidance calls for recovering the cost and deleting the Prescription Drug Event record, rather than reporting that correction as DIR. Putting medicine back on the shelf does not return the payer’s money.
The negotiated-price change for 2024 brought pharmacy price concessions into the price at the counter. Annual pharmacy DIR reporting continued, pairing the estimated concession with the difference between negotiated price and final reimbursement. Someone reconciling pharmacy payments may know whether the initial claim, later adjustment and sponsor report ultimately tell the same story.
The agreement and the payer’s reporting rules determine which affiliate receipts must be passed through or reported. The payment’s label is only the beginning of that inquiry.
For Part D, the sponsor’s contractual right to receive money and its duty to report drug-cost reductions are separate. The reporting rules can reach remuneration retained by an intermediary. The Centers for Medicare & Medicaid Services’ annual guidance also distinguishes qualifying manufacturer service fees from amounts above fair market value that must be reported as DIR.
Elixir agreed to $101 million in fixed payments under its settlement. The government alleged that the Part D sponsor excluded retained manufacturer rebates from its reports by classifying them as service fees. The alleged falsehood lay in how the money entered the government’s reconciliation. Manufacturer agreements, actual receipts and the sponsor’s classification connect that story more clearly than an account labeled service revenue.
A pharmacy audit can show a recurring claim problem, who learned about it and what happened afterward. The finding, the company’s response, subsequent claims and any refund belong together.
The government’s CVS insulin complaint alleged that PBM audits repeatedly identified invalid supply data, premature refills and quantities exceeding prescriptions. It also alleged that PBMs issued chargebacks and management failed to take the necessary corrective steps. For someone in audit, billing or software, the important question is whether the same setting kept producing the same problem after the warning.
The sponsor’s oversight matters too. In its Group Health Cooperative pharmacy-fee audit, the Department of Health and Human Services’ Office of Inspector General could not validate revised DIR submissions without adequate PBM support. The recommendations were later implemented. A submitted total still needs the records behind it.
Dispensing records, claim changes, contracts and audit responses can connect what the payer was told to what happened. A pharmacist, pharmacy technician or PBM analyst may see only one part of that transaction. We work with you to connect it to the rest.
For a changed product code or rebilled claim, the original transaction and later versions show what changed. For a pharmacy-created prior authorization, the prescriber’s actual approval and the information sent to the payer are central. For rebate reporting, the manufacturer receipt and sponsor submission connect the money to the account given of it.
We build the evidence picture with you, including who holds the records and what each system captures. Questions about access, confidentiality, patient information or your own involvement belong in that conversation.
The payer and conduct determine the relevant agency and whistleblower route. Start with our whistleblower experts so we can assess the connection to government health care payments and the case your information can support. We work out the reporting route with you, including which payer funded the claim and which government program received the report.
No. A settlement states what the parties agreed to resolve. The whistleblower’s reward is a share of the recovery. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
A package can resolve several cases and allocate money among different government claims. The agreement and award terms identify the recovery to which a share applies. We assess the false payment, the supporting evidence and the potential recovery in your case, rather than apply a headline amount to your information.
No. The Supreme Court decided how to assess what the company knew. Its decision concerned the company’s beliefs when it submitted claims, rather than an explanation developed afterward.
The case arose from cash discounts and the usual and customary prices reported to government programs. Usual and customary price is the public charge as defined by the payer’s rule. A cash transaction and a claim field have to be connected to the amount the program paid.
The later SuperValu court order records a split result: the jury found the company knew, but did not find that the challenged conduct caused the claimed harm. The company won the judgment.
For us, the practical question is what the false information changed in the payer’s decision. The person who knows the reimbursement calculation may contribute something different from the person who knows management received a warning. Both accounts can matter.
The strongest account connects what was represented, the payer, the applicable agreement or rule, the people who knew and the payment affected. Your contribution may be a single connection: why a paid order left a queue, why a refill date moved, or why a manufacturer receipt disappeared from a report.
We follow that connection across the dispensing, billing, contract and reconciliation records with you. That is how an operational detail becomes a specific account of who paid, who benefited and what information moved the money.
If you know the setting, instruction or contract decision behind a pharmacy claim or PBM report, talk with our Whistleblower Experts about building your strongest pharmacy fraud case. We connect your firsthand knowledge to the payment and bring in pharmacy and PBM fraud whistleblower lawyers who understand the arrangement. We stay beside you as your partners through the pursuit of the case and your share of the recovery.